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Abstract
Background: Fetoscopic LASER coagulation of the placental anastomoses has changed the prognosis of twin-twin
transfusion syndrome. However, the prematurity rate in this cohort remains very high. To date, strategies proposed
to decrease the prematurity rate have shown inconclusive, if not unfavourable results.
Methods: This is a randomised controlled trial to investigate whether a prophylactic cervical pessary will lower the incidence
of preterm delivery in cases of twin-twin transfusion syndrome requiring fetoscopic LASER coagulation. Women eligible for the
study will be randomised after surgery and allocated to either pessary or expectant management. The pessary will be left in
place until 37 completed weeks or earlier if delivery occurs. The primary outcome is delivery before 32 completed weeks.
Secondary outcomes are a composite of adverse neonatal outcome, fetal and neonatal death, maternal complications,
preterm rupture of membranes and hospitalisation for threatened preterm labour. 352 women will be included in order to
decrease the rate of preterm delivery before 32 weeks’ gestation from 40% to 26% with an alpha-error of 0.05 and 80% power.
Discussion: The trial aims at clarifying whether the cervical pessary prolongs the pregnancy in cases of twin-twin transfusion
syndrome regardless of cervical length at the time of fetoscopy.
Trial registration: ClinicalTrials.gov Identifier: NCT01334489. Registered 04 December 2011.
Keywords: Twin-to-twin transfusion syndrome, Fetoscopic LASER coagulation, Cervical length, Preterm delivery,
Cervical pessary
Background
Fetoscopic LASER coagulation of placental anastomoses
(FLC) with or without Solomon technique [1] is the
treatment of choice for severe Twin-to-Twin Transfu-
sion Syndrome (TTTS) [2]. This procedure completely
changed the natural history of TTTS [3]. However,
although this first and most important step was taken
and survival rates and neurological outcomes improved,
premature births remain a serious concern: 41% of
patients will deliver before 32 completed weeks [4].
Therefore, an effort to reduce prematurity is required.
Cervical pessary placement could constitute an option to
reduce prematurity, regardless of cervical length at the
time of fetoscopy.
Transvaginal ultrasound permits the identification of
twin pregnancies at high risk of preterm delivery [5, 6].
It is known that cervical length (CL) plays a role in the
onset of preterm birth. The pathophysiology of prema-
ture ripening of the cervix varies between singleton and
multiple pregnancies with twin pregnancies having a
higher prevalence of short cervix at 23 weeks [7].
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Regarding TTTS, Yamamoto et al. showed that short CL
before treatment is an independent risk factor for pre-
term delivery [8].
The prematurity rate in cases of severe TTTS in pa-
tients with long cervix treated by FLC remains very high
[9–11]. Although many cases are delivered prematurely
for medical indications (mainly selective intrauterine
growth restriction), a large proportion will also develop
spontaneous preterm labour [12].
Information is lacking regarding the best therapeutic
option in patients with short cervix who also require fe-
toscopy [9–11]. Salomon et al. suggested the use of an
emergency cerclage in cases of TTTS with a short cervix
at the time of surgery [13]. In this observational study,
the emergency cerclage could prolong pregnancy and
improve perinatal outcomes. It was the first study to
demonstrate a potential benefit to prevent premature
delivery in such cases. Nevertheless, emergency cerclage
continues to be an invasive procedure requiring anaes-
thesia. It also bears the risk of infection, local inflamma-
tory reactions and premature rupture of membranes,
although these were not observed in the Salomon study
[14–16]. In current practice an emergency cerclage is
usually performed for a cervical length less or equal to
15 mm after fetoscopic surgery in cases of TTTS, al-
though the benefit of the cerclage in these cases has
been recently questioned [17].
Previous studies in singleton and twin pregnancies
showed that the use of a cervical pessary significantly
reduces the frequency of birth before 32 weeks and pro-
longs the pregnancy [18–20]. The advantages of using a
cervical pessary are that it is a non-invasive, operator-
independent, easy to use device, does not require anaes-
thesia and can easily be removed when necessary.
Our group performed a pilot study in which we placed
an Arabin cervical pessary in cases of TTTS with FLC
and retrospectively compared the outcomes with a con-
trol group. There was a lower rate of preterm birth and
less neonatal morbidity in the pessary group [21].
The ProTWIN Trial [22], despite concluding that in
unselected women with multiple pregnancies prophylac-
tic use of a cervical pessary does not reduce poor peri-
natal outcome, found a significant difference in perinatal
outcome for the subgroup of monochorionic pregnan-
cies (14% vs. 25% in the control group).
The aim of this trial is to investigate whether a
prophylactic cervical pessary will lower the incidence of
preterm delivery in cases of twin-twin transfusion syn-
drome requiring fetoscopic laser coagulation.
Methods/design
Aims
We will perform a randomised trial (the PECEP LASER
Trial: Arabin Cervical Pessary for prevention of preterm
birth in cases of Twin-to-Twin Transfusion Syndrome
treated by Fetoscopic Laser coagulation) to assess the ef-
fect of the Arabin cervical pessary on the rate of preterm
delivery in cases of monochorionic pregnancies with
twin-twin transfusion syndrome requiring fetal therapy.
This is a multicenter study to be conducted in the Hos-
pital Universitari Vall d’Hebron in Barcelona (Catalunya,
Spain), the Universitaire Ziekenhuizen in Leuven (Belgium),
and the University Medical Centrer Hamburg-Eppendorf
(UKE) in Hamburg (Germany). All centers have approval
from the respective Medical Ethics Committees to conduct
the trial.
The trial was registered in ClinicalTrials.gov in
December 4th, 2011 (https://www.clinicaltrials.gov/ct2/
show/NCT01334489?term=NCT01334489&recrs=a&r-
ank=1). The trial identifier is NCT01334489.
The study is open for other centres who wish to
participate.
Participants
All women presenting with a monochorionic-diamniotic
pregnancy with severe twin-twin transfusion syndrome
between 16 and 26 weeks are eligible for the study with
the exception of pregnancies complicated by major con-
genital abnormalities, uterine malformations, placenta
praevia, active vaginal bleeding or spontaneous rupture
of membranes at the time of randomization. Also pa-
tients with contraindication for pessary placement as
painful regular uterine contractions, or a cervical cerc-
lage in place will be excluded [20], as well as cases of de-
mise of both twins after surgery.
Gestational age will be determined through menstrual
history and first trimester scan.
Procedures, recruitment, randomisation and collection of
data
The Fetal Medicine Teams in the participating centres
will counsel all women being referred for suspected
TTTS. When fetoscopic LASER is planned, one of the
Fetal Medicine specialists will confirm that the patient
fulfils the inclusion criteria, and the study will be pro-
posed. The patients will be informed about the intended
therapeutic effect and possible side effects. The patient
will be given an information sheet and if possible, she
will have 24 h time to reflect on participation. If they
agree, after obtaining their informed consent, they will
be randomised in two groups: Usual management or cer-
vical pessary placement.
The randomisation will be computed on-line at the
platform for electronic data management based at the
Catalan Institute of Pharmacology (ICF) where all data
will be collected in a worldwide accessible online data-
base. Each centre will have its own randomisation list
and randomisation will be 1:1 for pessary placement
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versus control. Only a participant identification number
in the electronic database will identify the participants.
All documents will be stored securely and only access-
ible by trial staff and authorized personnel.
The study is not blinded.
Baseline characteristics of the women, the pregnancies
and issues on the TTTS and the surgery will be re-
corded. The cervical length will be recorded before and
after surgery and every 4 weeks until delivery. We will
also record complications of the surgery, complications
by the pessary and perinatal results.
Intervention
For women allocated into cervical pessary group, the de-
vice will be inserted within 72 h after fetal surgery in the
assessment room of the outpatients Department. This
procedure does not require anaesthesia and does not
need to be performed in an operating theatre.
All patients, both the pessary and the expectant man-
agement group, will be followed as in routine mono-
chorionic follow-up, with clinical clinical review and
ultrasound every two weeks. We will perform a transva-
ginal ultrasound for measuring cervical length every four
weeks and will also assess the correct placement of the
pessary.
Further surveillance of the pregnancy will not be influ-
enced by the participation in the study. If the cervical
length decreases later on during the pregnancy, the ges-
tation will be managed according to the local protocol.
However, cervical cerclage or progesterone will not be
allowed in any case during the rest of the pregnancy.
The pessary will be removed at 37 weeks of gestation
or before if any unexpected event or spontaneous deliv-
ery occurs. The indications to remove the pessary before
this time will be: active bleeding, persistent contractions
after tocolysis and premature rupture of the membranes
after 34 weeks. After removing the pessary, the obstet-
rical management will be done as usual.
The study will close after the home discharge of the
last newborn, as neonatal adverse outcomes will also be
recorded.
Outcomes
The primary outcome will be delivery before 32 com-
pleted weeks.
Secondary outcomes will be related to the delivery and
perinatal results: preterm delivery before 28, 30, 34 and
37 weeks; preterm rupture of membranes; hospitalisation
for threatened preterm labour (including the need of toco-
lysis and fetal lung maturation); fetal or neonatal death;
composite neonatal morbidity (any of intraventricular
haemorrhage, necrotising enterocolitis, retinopathy of pre-
maturity, proven or suspected sepsis, need of Neonatal In-
tensive Care, need of ventilation, phototherapy, antibiotics
or blood transfusion). We will also record significant ma-
ternal adverse effects, mainly due to the pessary.
A long-term follow-up of the babies is not planned.
Statistics
Expected sample size
We based our sample size calculations on the assumption
that the pessary reduces the primary outcome (preterm
birth <32 weeks) from 40% in the control group to 26% in
the pessary group [18]. With a study power of 80% and an
alpha error of 5%, (assuming an effect size of 0.5 (moder-
ate) and expecting a potential drop out rate of 10%), the
required sample size has been estimated to be 352 pa-
tients, 176 cases in each arm of the study. We will perform
2 interim analyses, so the p-value would be set at 0.045
(O’Brien-Fleming rule) [23] instead of 0.05 and we would
therefore need to recruit 182 patients in each arm.
Data analysis
A descriptive analysis by preterm birth will be carried
out calculating means and medians for quantitative vari-
ables and proportions for categorical variables. T-test or
Mann-Whitney test and Pearson Chi-squared or Fisher
test will be used for comparing among exposure and
outcomes groups per pregnancy. A multivariate logistic
regression will be fitted to control for possible con-
founders. Relative risks and 95% confidence interval will
be calculated for the outcomes.
For fetal and neonatal outcomes, multilevel models
will be used to analyse continuous outcomes and gener-
alized estimating equations will be used to assess cat-
egorical outcomes to adjust for the clustering of twins in
mothers. A secondary analysis of length of gestation
after fetoscopy will be plotted on a staggered-entry
Kaplan-Meier curve where gestational age at birth (in
days) will be the final event. Elective A Mantel-Cox test
will be performed to test statistically for significant dif-
ferences in the time interval between fetoscopy and
birth. All analyses will be carried out with SPSS® 19.0
statistical package (IBM Company SPSS Inc. Headquar-
ters, Chicago, Illinois. USA). Statistical significance will
be accepted in all cases with a p < 0.05.
We do not expect to have lost data because this study
has a short follow-up time. We will also perform a per-
protocol analysis.
We also intend to perform a subgroup analysis accord-
ing the cervical length: over 25 mm, 15 to 25 mm and
less than 15 mm. We decided to perform the subgroup
analysis with these cut-off lengths because 25 mm is
around the 5th centile for cervical length for twins less
than 22 weeks’ gestation [24] and some groups perform
cervical cerclage in TTTS patients with CL below
15 mm [13].
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Interim analysis
An interim analysis of efficacy and futility will be per-
formed after each 100 patients enrolled in the study
using the O’Brien & Fleming rule [23] for efficacy and
conditional power calculation to assess futility. The trial
will be stopped early if after the first 100 patients the dif-
ference has a p-value of <0.0001, if after 200 patients the
p-value reaches a difference of <0.004. The interim ana-
lyses as well as the final outcome adjudication will be
performed blinded to group assignment.
Study calendar
We expect patient recruitment to take approximately
3 years. One more year of duration is estimated for ana-
lysis and publication of the results.
Discussion
Fetoscopic LASER coagulation of the placental anasto-
moses is the treatment of choice for severe twin-twin
transfusion syndrome as this treatment has completely
changed the prognosis in terms of survival of these ba-
bies. However, the morbidity of these babies is still very
high, both at short and long term, mainly due to the
high rates of prematurity.
The rate of spontaneous preterm delivery is high, even if
the cervical length is in the normal range at the time of the
surgery [25]. Almost half of these twins deliver around
32 weeks and most of them are electively delivered around
34 weeks [11, 12], thus we decided that the best cut-off
should be “delivery before 32 weeks”, gaining at least two
weeks in this group. Likewise, most of the babies are deliv-
ered preterm due to complications of the monochorionic
placenta such as selective intrauterine growth restriction,
twin anemia-policytemia sequence (TAPS) or recurrent
TTTS. As this is an intention-to-treat study, the rate of
iatrogenic births is expected to be the same in both groups.
In the last decade, some strategies to prevent preterm
delivery in twins have been published: bed rest is not
useful in twin pregnancies [26], and the use of the cer-
vical cerclage has been questioned [27], despite some
groups using it in cases of short cervical length after the
fetal surgery [13].
The cervical pessary is a simple and easy-to-use
method to prevent preterm birth that has been proven
to be effective in singleton pregnancies [20], twins [18]
and in the subgroup of monochorionic twins in the
ProTwin Trial [22].
As far as we know, there is only one pilot study in this
field [21], with favourable results for the pessary. There-
fore, a trial that compares the use of the cervical pessary
to expectant management in cases of twin-twin transfu-
sion syndrome undergoing fetoscopic LASER coagula-
tion is needed.
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